Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study

BACKGROUND: A recent phase 3 study demonstrated that treatment with tanezumab, a nerve growth factor inhibitor, or nonsteroidal anti-inflammatory drugs (NSAIDs) improves pain and physical function in participants with moderate-to-severe osteoarthritis (OA) of the hip or knee. Here, we evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales: Neogi, Tuhina, Hunter, David J., Churchill, Melvin, Shirinsky, Ivan, White, Alexander, Guermazi, Ali, Omata, Masanari, Fountaine, Robert J., Pixton, Glenn, Viktrup, Lars, Brown, Mark T., West, Christine R., Verburg, Kenneth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966257/
https://www.ncbi.nlm.nih.gov/pubmed/35351194
http://dx.doi.org/10.1186/s13075-022-02759-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8966257/
https://www.ncbi.nlm.nih.gov/pubmed/35351194
http://dx.doi.org/10.1186/s13075-022-02759-0

Ejemplares similares